CN112730826A - 一种人磷酸化血管扩张刺激磷蛋白磁微粒化学发光免疫定量检测试剂盒及其检测方法和应用 - Google Patents
一种人磷酸化血管扩张刺激磷蛋白磁微粒化学发光免疫定量检测试剂盒及其检测方法和应用 Download PDFInfo
- Publication number
- CN112730826A CN112730826A CN202011532533.6A CN202011532533A CN112730826A CN 112730826 A CN112730826 A CN 112730826A CN 202011532533 A CN202011532533 A CN 202011532533A CN 112730826 A CN112730826 A CN 112730826A
- Authority
- CN
- China
- Prior art keywords
- vasodilator
- stimulated phosphoprotein
- human phosphorylated
- kit
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010054220 vasodilator-stimulated phosphoprotein Proteins 0.000 title claims abstract description 75
- 102000049398 Vasodilator-stimulated phosphoproteins Human genes 0.000 title claims abstract description 74
- 239000006249 magnetic particle Substances 0.000 title claims abstract description 38
- 238000001514 detection method Methods 0.000 title claims abstract description 36
- 239000011248 coating agent Substances 0.000 claims abstract description 36
- 238000000576 coating method Methods 0.000 claims abstract description 36
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 30
- 102000004190 Enzymes Human genes 0.000 claims abstract description 29
- 108090000790 Enzymes Proteins 0.000 claims abstract description 29
- 239000011324 bead Substances 0.000 claims abstract description 27
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229960000711 alprostadil Drugs 0.000 claims abstract description 23
- 108010089430 Phosphoproteins Proteins 0.000 claims abstract description 22
- 102000007982 Phosphoproteins Human genes 0.000 claims abstract description 22
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims abstract description 22
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims abstract description 18
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims abstract description 18
- 238000005336 cracking Methods 0.000 claims abstract description 16
- 206010047141 Vasodilatation Diseases 0.000 claims abstract description 11
- 238000003018 immunoassay Methods 0.000 claims abstract description 11
- 230000024883 vasodilation Effects 0.000 claims abstract description 11
- 239000007853 buffer solution Substances 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 238000007885 magnetic separation Methods 0.000 claims description 12
- 230000009089 cytolysis Effects 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 10
- 238000011534 incubation Methods 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000007983 Tris buffer Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- 238000004140 cleaning Methods 0.000 claims description 6
- 239000002086 nanomaterial Substances 0.000 claims description 5
- 239000008055 phosphate buffer solution Substances 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 238000004020 luminiscence type Methods 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 229940127218 antiplatelet drug Drugs 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 238000000504 luminescence detection Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 abstract description 10
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 238000008157 ELISA kit Methods 0.000 abstract description 6
- 230000036046 immunoreaction Effects 0.000 abstract description 4
- 239000007790 solid phase Substances 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000011859 microparticle Substances 0.000 abstract description 2
- 239000000463 material Substances 0.000 description 13
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 12
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 12
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 230000026731 phosphorylation Effects 0.000 description 11
- 238000006366 phosphorylation reaction Methods 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000007865 diluting Methods 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 5
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 5
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 5
- 229960003009 clopidogrel Drugs 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002101 lytic effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229940124549 vasodilator Drugs 0.000 description 4
- 239000003071 vasodilator agent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 2
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 2
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- -1 Vincultin Proteins 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000005281 excited state Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000003632 microfilament Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000006911 nucleation Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 238000011056 performance test Methods 0.000 description 2
- 230000010118 platelet activation Effects 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 108010059397 ENA-VASP proteins Proteins 0.000 description 1
- 102000038672 Ena/VASP family Human genes 0.000 description 1
- 108091073350 Ena/VASP family Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000007466 Purinergic P2 Receptors Human genes 0.000 description 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010023249 Zyxin Proteins 0.000 description 1
- 102000011177 Zyxin Human genes 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000011095 buffer preparation Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000000719 purinergic P2Y receptor antagonist Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/222—Platelet disorders
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Plasma & Fusion (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Description
物料 | 用量 |
三羟甲基氨基甲烷 | 2.42g |
氯化钠 | 18.00g |
Tween-20 | 0.50g |
牛血清白蛋白 | 50.00g |
Proclin300 | 1.00g |
物料 | 用量 |
三羟甲基氨基甲烷 | 2.42g |
氯化钠 | 18.00g |
Tween-20 | 1.00g |
牛血清白蛋白 | 50.00g |
Proclin300 | 1.00g |
物料 | 用量 |
Proclin300 | 1.00g |
物料 | 用量 |
三羟甲基氨基甲烷 | 2.42g |
氯化钠 | 18.00g |
Tween-20 | 1.00g |
胎牛血清 | 200mL |
Proclin300 | 1.00g |
浓度ng/mL | 发光值1 | 发光值2 | 均值 |
0.000 | 9985 | 9847 | 9916 |
6.125 | 464998 | 447115 | 456057 |
12.250 | 980998 | 953436 | 967217 |
25.000 | 1890029 | 1741507 | 1815768 |
50.000 | 3777745 | 3586306 | 3682026 |
100.000 | 7751427 | 7565142 | 7658285 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011532533.6A CN112730826A (zh) | 2020-12-23 | 2020-12-23 | 一种人磷酸化血管扩张刺激磷蛋白磁微粒化学发光免疫定量检测试剂盒及其检测方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011532533.6A CN112730826A (zh) | 2020-12-23 | 2020-12-23 | 一种人磷酸化血管扩张刺激磷蛋白磁微粒化学发光免疫定量检测试剂盒及其检测方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112730826A true CN112730826A (zh) | 2021-04-30 |
Family
ID=75604151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011532533.6A Pending CN112730826A (zh) | 2020-12-23 | 2020-12-23 | 一种人磷酸化血管扩张刺激磷蛋白磁微粒化学发光免疫定量检测试剂盒及其检测方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112730826A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113238062A (zh) * | 2021-07-13 | 2021-08-10 | 湖南菲思特精准医疗科技有限公司 | 一种用于人磷酸化血管扩张刺激磷蛋白光激化学发光均相免疫检测试剂盒及其检测方法 |
CN114002440A (zh) * | 2021-12-30 | 2022-02-01 | 湖南菲思特精准医疗科技有限公司 | 一种用于人磷酸化血管扩张刺激蛋白的酶联免疫检测试剂盒及其检测方法 |
CN114217069A (zh) * | 2021-11-19 | 2022-03-22 | 上海普然生物科技有限公司 | 一种用于神经元丝状蛋白磁微粒化学发光免疫检测试剂盒及其检测方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999024473A1 (en) * | 1997-11-07 | 1999-05-20 | Aventis Pharma Deutschland Gmbh | Antibodies against phosphorylated vasp (vasodilator-stimulated phosphoprotein), hybridoma cells for their preparation, and their use |
US20040146950A1 (en) * | 2002-11-21 | 2004-07-29 | The University Of North Carolina | Phosphoprotein detection reagent and methods of making and using the same |
CN102435753A (zh) * | 2011-08-31 | 2012-05-02 | 内蒙古科慧生物科技有限责任公司 | 糖化血红蛋白(HbAlc)定量测定试剂盒及其检测方法 |
CN102803505A (zh) * | 2009-06-12 | 2012-11-28 | 赛泰克斯生物公司 | 属于细胞信号通路的细胞内生物标记物的全血含量及其测量确定细胞群的活化的用途 |
CN108982861A (zh) * | 2018-07-26 | 2018-12-11 | 北京普恩光德生物科技开发有限公司 | 一种血管扩张型刺激磷蛋白检测试剂盒 |
CN109975499A (zh) * | 2019-05-05 | 2019-07-05 | 武汉大学 | 一种提升利托那韦药物抗癌有效性的检测方法 |
CN110514844A (zh) * | 2019-08-14 | 2019-11-29 | 湖南山河生物医学技术孵化中心(有限合伙) | 一种人五聚素3磁微粒化学发光免疫定量检测试剂盒及其制备方法 |
CN111596066A (zh) * | 2015-05-08 | 2020-08-28 | 分析科学莱布尼茨研究所Isas协会 | 鉴定用于凝血障碍的诊断和风险分层的标记蛋白的方法 |
-
2020
- 2020-12-23 CN CN202011532533.6A patent/CN112730826A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999024473A1 (en) * | 1997-11-07 | 1999-05-20 | Aventis Pharma Deutschland Gmbh | Antibodies against phosphorylated vasp (vasodilator-stimulated phosphoprotein), hybridoma cells for their preparation, and their use |
US20040146950A1 (en) * | 2002-11-21 | 2004-07-29 | The University Of North Carolina | Phosphoprotein detection reagent and methods of making and using the same |
CN102803505A (zh) * | 2009-06-12 | 2012-11-28 | 赛泰克斯生物公司 | 属于细胞信号通路的细胞内生物标记物的全血含量及其测量确定细胞群的活化的用途 |
CN102435753A (zh) * | 2011-08-31 | 2012-05-02 | 内蒙古科慧生物科技有限责任公司 | 糖化血红蛋白(HbAlc)定量测定试剂盒及其检测方法 |
CN111596066A (zh) * | 2015-05-08 | 2020-08-28 | 分析科学莱布尼茨研究所Isas协会 | 鉴定用于凝血障碍的诊断和风险分层的标记蛋白的方法 |
CN108982861A (zh) * | 2018-07-26 | 2018-12-11 | 北京普恩光德生物科技开发有限公司 | 一种血管扩张型刺激磷蛋白检测试剂盒 |
CN109975499A (zh) * | 2019-05-05 | 2019-07-05 | 武汉大学 | 一种提升利托那韦药物抗癌有效性的检测方法 |
CN110514844A (zh) * | 2019-08-14 | 2019-11-29 | 湖南山河生物医学技术孵化中心(有限合伙) | 一种人五聚素3磁微粒化学发光免疫定量检测试剂盒及其制备方法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113238062A (zh) * | 2021-07-13 | 2021-08-10 | 湖南菲思特精准医疗科技有限公司 | 一种用于人磷酸化血管扩张刺激磷蛋白光激化学发光均相免疫检测试剂盒及其检测方法 |
CN113238062B (zh) * | 2021-07-13 | 2021-09-28 | 湖南菲思特精准医疗科技有限公司 | 一种用于人磷酸化血管扩张刺激磷蛋白光激化学发光均相免疫检测试剂盒及其检测方法 |
CN114217069A (zh) * | 2021-11-19 | 2022-03-22 | 上海普然生物科技有限公司 | 一种用于神经元丝状蛋白磁微粒化学发光免疫检测试剂盒及其检测方法 |
CN114002440A (zh) * | 2021-12-30 | 2022-02-01 | 湖南菲思特精准医疗科技有限公司 | 一种用于人磷酸化血管扩张刺激蛋白的酶联免疫检测试剂盒及其检测方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112730826A (zh) | 一种人磷酸化血管扩张刺激磷蛋白磁微粒化学发光免疫定量检测试剂盒及其检测方法和应用 | |
US10472400B2 (en) | Cardiac troponin I ultra-sensitive detection reagent kit, and ultra-sensitive detection method therefor | |
WO2018133038A1 (zh) | 标记复合物及其制备方法、试剂盒、应用和检测系统 | |
CN107817354A (zh) | 一种白介素6的化学发光检测试剂盒及其制备方法 | |
CN109187973B (zh) | 用于检测神经元特异性烯醇化酶的化学发光免疫试剂盒 | |
CN112782156B (zh) | 一种壳多糖酶3样蛋白1试剂盒及其制备方法 | |
CN104634980A (zh) | 心肌肌钙蛋白i超敏检测试剂盒及超敏检测方法 | |
WO2016127301A1 (zh) | rT3化学发光免疫检测试剂盒及其检测方法和应用 | |
CN112730839B (zh) | 一种磁微粒化学发光法测定细胞角蛋白19片段含量的试剂盒 | |
ES2761427T3 (es) | Procedimientos para reducir interferencias | |
JP6440265B2 (ja) | フラッシュ・グロー型の1,2−ジオキセタン | |
CN108362895B (zh) | 叶酸检测试剂盒及其制备方法 | |
US11971407B2 (en) | Detection of anti-p53 antibodies | |
ES2277018T3 (es) | Metodo, ensayo y equipo para la cuantificacion de inhibidores de la proteasa del vih. | |
CN109917128B (zh) | 抗降钙素原抗体包被颗粒的方法 | |
CN112904023B (zh) | 一种降钙素原化学发光免疫检测试剂盒 | |
JP6832160B2 (ja) | 多重分析法を実行するための対照 | |
CN110531085A (zh) | 一种测定人体神经丝轻链蛋白含量的磁微粒化学发光检测试剂盒及其制备方法 | |
EP3929584A1 (en) | Method for measuring thyroglobulin | |
CN116381222A (zh) | 一种血清素发光免疫检测方法及血清素检测试剂盒 | |
EP4146765B1 (en) | A method and reagents for enhancing the chemiluminescent signal | |
Xie et al. | Sensitive colorimetric detection for lysozyme based on the capture of a fixed thiol-aptamer on gold nanoparticles | |
JP2018533017A (ja) | 多基体による検体検出 | |
CN112834739A (zh) | 一种磁微粒化学发光法测定人血中氨基末端脑利钠肽前体的试剂盒 | |
CN114217069A (zh) | 一种用于神经元丝状蛋白磁微粒化学发光免疫检测试剂盒及其检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Yang Guoping Inventor after: Liu Lihui Inventor after: Cao Yu Inventor after: Li Mingyong Inventor after: Guo Chengxian Inventor after: Fan Yan Inventor after: Gong Liying Inventor before: Yang Guoping Inventor before: Liu Lihui Inventor before: Cao Yu |
|
CB03 | Change of inventor or designer information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220322 Address after: 410005 floor 6, building 4, Shanhe medical and Health Industrial Park, No. 1048, Zhongqing Road, shaping street, Kaifu District, Changsha City, Hunan Province Applicant after: HUNAN YUANJING BIOTECHNOLOGY CO.,LTD. Address before: 410006 No.138, tongzipo Road, Yuelu District, Changsha City, Hunan Province Applicant before: THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH University Applicant before: Hunan Yuanjing Biotechnology Co., Ltd |
|
TA01 | Transfer of patent application right |